TMS Therapy New Jersey logo

Evidence and research

TMS FDA Clearances: Depression, OCD, Smoking, and More

September 16, 2026 · 7 min read · By TMS Therapy New Jersey editorial team

TMS has FDA-cleared uses for adult depression, OCD, short-term smoking cessation, anxiety symptoms accompanying adult depression, and adolescent depression within specific device labeling. The milestones below explain those indications using the linked regulatory documents and manufacturer announcements; “cleared” does not mean every TMS device can treat every condition or that treatment will work for everyone.

What FDA clearance actually means

Transcranial magnetic stimulation, or TMS, uses magnetic pulses to stimulate targeted areas of the brain. It is delivered using a medical device, so its regulatory language differs from the language patients commonly hear about medications.

FDA clearance is permission to market a particular device for a defined intended use. For devices cleared through the 510(k) pathway, the FDA evaluates substantial equivalence to a legally marketed device. The adult depression clearance document illustrates that device-specific process.

Not every initial authorization follows the same pathway. The FDA reviewed the initial OCD device through its De Novo pathway, as explained in its OCD marketing authorization announcement. Although “FDA-cleared TMS” is useful shorthand, the exact authorization and labeling matter more than the slogan.

For a patient, the practical questions are:

  • Does the device have an indication covering my diagnosis?
  • Does its labeling cover my age and treatment history?
  • Is the proposed treatment consistent with that labeling?
  • If not, which part of the proposed care is off-label?

This article explains the milestones in the supplied sources, rather than cataloging every device-specific clearance or later labeling change.

Adult depression: the initial clearance

The first US TMS device clearance for adult major depressive disorder came in 2008. The supplied NeuroStar clearance document covers adults who had failed an adequate antidepressant trial.

That treatment-history requirement matters. “TMS is cleared for depression” is an incomplete description if it leaves out the device, diagnosis, and eligibility criteria. The initial clearance was not a blanket authorization for every depressive symptom or every patient experiencing low mood.

A consultation should establish the diagnosis and review previous treatment, including medication dose, duration, tolerability, and response. A prescriber can then explain whether the proposed device's current labeling fits the patient's situation.

FDA clearance does not promise remission or eliminate the need to discuss alternatives, risks, and ongoing care. Our overview of conditions considered for TMS can help organize questions, but a directory category is not a substitute for device-specific labeling.

OCD: a distinct deep TMS indication

In 2018, the FDA authorized a deep TMS device for obsessive-compulsive disorder, supported by a randomized, sham-controlled trial, according to the FDA announcement.

This was a separate indication, not simply an extension of the depression treatment label. The relevant device and OCD treatment approach matter; a clinic offering TMS for depression does not automatically offer an FDA-authorized OCD treatment.

The published multicenter OCD trial reported greater improvement in OCD symptoms with active deep TMS than with sham treatment. That supports a treatment option, not an expectation that every patient will respond or that established OCD care becomes unnecessary.

For patients, an important distinction is between a clinician proposing the cleared OCD approach and proposing a different, off-label TMS approach for OCD. Ask which device will be used, how treatment is delivered, and how it relates to existing care. Our guide to TMS for obsessive-compulsive disorder provides a starting point for that discussion.

Smoking cessation: an aid with a short-term indication

In 2020, BrainsWay announced FDA clearance of deep TMS as an aid to short-term smoking cessation in adults, according to its clearance announcement. This supplied source is a manufacturer announcement, not an FDA-hosted decision document.

The phrase “aid to short-term smoking cessation” sets important boundaries. It should not be rewritten as a guaranteed way to quit, a permanent cure for nicotine dependence, or authorization to treat every substance use disorder.

The manufacturer reported better short-term quit outcomes with active treatment than with sham in the supporting trial, but that does not establish that an individual patient will stop smoking or remain abstinent indefinitely. Those findings and their short-term framing are described in the same announcement.

A prescriber should explain how the proposed treatment fits into smoking-cessation care. TMS proposed for another addiction must be assessed separately; this smoking indication cannot establish that another use is FDA-cleared.

Anxiety symptoms in adult depression: not all anxiety disorders

In 2022, the FDA cleared NeuroStar for treating anxiety symptoms in adults with major depressive disorder, as documented in clearance K222230. This is often called an anxious-depression indication.

The diagnostic context is essential. Anxiety symptoms accompanying major depressive disorder are not interchangeable with a standalone anxiety disorder. This clearance does not, by itself, authorize treatment of generalized anxiety disorder or panic disorder without the indicated depressive diagnosis.

If a clinic advertises “FDA-cleared TMS for anxiety,” ask it to explain the full indication. Is the treatment addressing anxiety symptoms within adult major depressive disorder, or is it being proposed off-label for a separate diagnosis?

Both the diagnosis and the intended treatment target should be clear before consent. A prescriber can explain the rationale without treating the anxious-depression label as a universal anxiety clearance.

Adolescent depression: an add-on indication

In 2024, Neuronetics announced NeuroStar clearance for major depressive disorder in patients aged 15–21, described as a first-line add-on treatment. These details come from the manufacturer's announcement.

The age range and add-on wording are part of the indication, not incidental details. This announcement does not establish clearance for younger children, every adolescent mental health condition, or all TMS devices.

“Add-on” means treatment alongside other care, rather than a claim that TMS replaces a patient's whole treatment plan. “First-line” in the announcement should not be interpreted as a recommendation that every eligible young person begin with TMS.

Families should ask how the proposed care matches current labeling, how consent and participation will be handled, and how symptoms and safety will be monitored. The consultation should also clarify who coordinates the young person's ongoing depression care.

What off-label treatment means for a patient

Off-label use means a legally marketed device is being used outside its cleared labeling. The difference might involve the diagnosis, patient population, or treatment approach.

Off-label does not automatically mean inappropriate, but it also does not mean the FDA has reviewed and cleared that particular use. A clinician's ability to offer treatment is a different question from its regulatory status, supporting evidence, or insurance coverage.

Before consenting, ask:

  • What specifically makes this use off-label?
  • What evidence supports it, and what remains uncertain?
  • What alternatives and risks should I understand?
  • How will we assess benefit and decide whether to continue?
  • What coverage or authorization has my insurer confirmed?

Someone comparing options near Princeton or Jersey City should ask these same questions rather than relying on “FDA-cleared” in a practice description. Bring your treatment history to a consultation with a prescriber, and use our TMS frequently asked questions to prepare. Clearance helps define an available option; individualized assessment determines whether it belongs in the discussion.

References

Ready to talk to a New Jersey clinic?

Send one request and we'll match you with providers who take your insurance.

By submitting you agree we may share your details with the provider you selected so they can contact you. This form is not for medical emergencies — call 911 or dial 988.

Keep reading

Find TMS near you